1786 Stock Overview
Manufactures and sells hyaluronic acid medical products in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
SciVision Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$123.00 |
| 52 Week High | NT$144.00 |
| 52 Week Low | NT$74.00 |
| Beta | 0.79 |
| 1 Month Change | 29.88% |
| 3 Month Change | 18.27% |
| 1 Year Change | 61.42% |
| 3 Year Change | 159.77% |
| 5 Year Change | 116.25% |
| Change since IPO | 307.52% |
Recent News & Updates
Recent updates
SciVision Biotech Inc.'s (TWSE:1786) 25% Share Price Surge Not Quite Adding Up
Jan 13
Is Now The Time To Put SciVision Biotech (TWSE:1786) On Your Watchlist?
Oct 11SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Aug 30SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's
Jul 22SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50
Jun 28SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Jun 14SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly
Jun 04Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio
Apr 01Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Apr 20SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital
Apr 02Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?
Mar 15Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Feb 25Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?
Feb 05Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Jan 18Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?
Jan 01
SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years
Dec 14Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Nov 25Shareholder Returns
| 1786 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | 2.5% | 1.7% | 4.4% |
| 1Y | 61.4% | -6.1% | 28.8% |
Return vs Industry: 1786 exceeded the TW Medical Equipment industry which returned -6.1% over the past year.
Return vs Market: 1786 exceeded the TW Market which returned 28.8% over the past year.
Price Volatility
| 1786 volatility | |
|---|---|
| 1786 Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 4.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1786 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1786's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Tai Xian Han | www.scivision.com.tw |
SciVision Biotech Inc. manufactures and sells hyaluronic acid medical products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in the wholesale of medical equipment; and provides management consulting services.
SciVision Biotech Inc. Fundamentals Summary
| 1786 fundamental statistics | |
|---|---|
| Market cap | NT$8.83b |
| Earnings (TTM) | NT$216.02m |
| Revenue (TTM) | NT$831.36m |
40.9x
P/E Ratio10.6x
P/S RatioIs 1786 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1786 income statement (TTM) | |
|---|---|
| Revenue | NT$831.36m |
| Cost of Revenue | NT$209.66m |
| Gross Profit | NT$621.70m |
| Other Expenses | NT$405.68m |
| Earnings | NT$216.02m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.01 |
| Gross Margin | 74.78% |
| Net Profit Margin | 25.98% |
| Debt/Equity Ratio | 7.5% |
How did 1786 perform over the long term?
See historical performance and comparisonDividends
2.0%
Current Dividend Yield79%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 23:06 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SciVision Biotech Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Weiyu Li | Capital Securities Corporation |